Expert opinions--consensus documents--systematic overviews--is the value for clinicians increasing?
Glimelius
Bengt
B
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy; D003245:Consensus Statements as Topic; D005104:Expert Testimony; D005260:Female; D006801:Humans; D015201:Meta-Analysis as Topic; D016032:Randomized Controlled Trials as Topic; D012004:Rectal Neoplasms / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D000068258:Bevacizumab; D000068818:Cetuximab